Takeda enters collaboration and licensing agreement with zedira and dr. falk pharma to develop first-in-class celiac disease therapy

Osaka, japan & freiburg, germany & darmstadt, germany--(business wire)--takeda (tse:4502/nyse:tak), zedira and dr. falk pharma gmbh today announced a collaboration and licensing agreement to develop zed1227/tak-227, a phase 2b investigational therapy for the treatment of celiac disease.
TAK Ratings Summary
TAK Quant Ranking